Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lactulose on Protein-Bound Uremic Toxin Lowering in Pre-dialysis Chronic Kidney Disease Patients
TCTR20260212002Phase 2Recruiting
- Sponsor
- Thai Red Cross Society
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lactulose in chronic kidney disease (CKD) (2 arms), sponsored by Thai Red Cross Society. Primary endpoint: Protein-bound uremic toxin levels. Started Oct 2024; status: recruiting.
02
Drugs
lactulose
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on TCTR20260212002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260212002.